Initially employed in the treatment of malignant melanoma and lung cancer, this technique involves the administration of monoclonal antibodies that target specific cell proteins such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1). This evidence concerns the gene PDCD1 and lung carcinoma.